Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bioavailability Study of Leflunomide Tablets Under Fed Conditions

This study has been completed.
Sponsor:
Collaborator:
Novum Pharmaceutical Research Services
Information provided by:
Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier:
NCT00653003
First received: April 1, 2008
Last updated: April 3, 2008
Last verified: April 2008

April 1, 2008
April 3, 2008
December 2003
January 2004   (final data collection date for primary outcome measure)
Rate and Extend of Absorption [ Time Frame: 24 Hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00653003 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bioavailability Study of Leflunomide Tablets Under Fed Conditions
To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fed Conditions

To compare the single-dose Bioavailability of Kali and Aventis

To compare the relative Bioavailability of leflunomide 20mg tablets with that of ARAVA 20mg tablets in healthy female subjects under fed conditions

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
To Determine Bioequivalence Under Fed Conditions.
  • Drug: Leflunomide
    tablets, 20mg, single-dose
    Other Name: ARAVA
  • Drug: ARAVA
    Tablets, 20mg, single-dose
    Other Name: Leflunomide
  • Experimental: A
    Subjects received Kali formulated product under fed conditions
    Intervention: Drug: Leflunomide
  • Active Comparator: B
    Subjects received Aventis formulated products under fed conditions
    Intervention: Drug: ARAVA
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
62
January 2004
January 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects will meet all of the following criteria within 30 days prior to first drug administration(except inclusion #8)
  • Healthy, surgically sterile (hysterectomy, bilateral oophorectomy) or postmenopausal (for al least 1 year)female subjects, 18 to 65 years of age(inclusive)
  • Indicate non-child bearing status by one of the following criteria:

Indication of successful hysterectomy. No spontaneous menses for al least 1 year, must have luteinizing hormone (LH) and follicle stimulating hormone(FSH) levels within postmenopausal range.

Indication of successful bilateral oophorectomy.

  • Body weight within 20% of the appropriate weight for the subject's height and frame (as published in the 1983 Metropolitan Life Insurance Company Scale, Statistical Bureau)
  • Negative for:

HIV Hepatitis B surface antigen and Hepatitis C antibody Urine tests for drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).

Serum HCG consistent with pregnancy.

  • No significant disease or clinically significant findings in a physical examination.
  • No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram(ECG)
  • Subjects who have received leflunomide within 4 months must have an A77-1726(Metabolite) level below 0.01ug/ml and no subsequent administration of leflunomide since that test. Note: The 30 day screening limit does not apply to this inclusion criterion.
  • Be informed of the nature of the study and given written consent prior to receiving any study procedures.

Exclusion Criteria:

  • Subject fulfilling any of the following criteria will be excluded from the study.
  • Known history or presence of any clinically significant medical condition.
  • Known or suspected carcinoma.
  • Known history or presence of:
  • Hypersensitivity or idiosyncratic reaction to leflunomide and/or any other drug substances with similar activity.
  • Alcoholism within the last 12 months.
  • Drug dependence and/ or substance abuse.
  • On a special diet within 4 weeks prior to drug administration(e.g. liquid, protein, raw food diet).
  • Participated in another clinical trail or received an investigational product 30 days prior to drug administration.
  • Donated up to 250 ml of blood in the past 45 days OR donated from 250 ml to 500 ml in the past 45 days OR donated 501 ml or more of blood in the past 56 days (based on the Canadian Blood Services guideline for blood donation).
  • Requirement of any medication (prescription and/ or over-the-counter) on a routine basis, with the exception of hormonal replacement therapy, nutritional supplements and/or occasional use of common analgesics.
  • Difficulty fasting or consuming the standard meals.
Female
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00653003
2004-704
No
Dr. Alfred Elvin/Director Biopharmaceutics, Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc.
Novum Pharmaceutical Research Services
Principal Investigator: Xueyu Chen Pharma Medica Research Inc.
Par Pharmaceutical, Inc.
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP